Dr. Groisberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
195 Little Albany St
New Brunswick, NJ 08901Phone+1 732-235-2465Fax+1 732-235-6797
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2015 - 2018
Yale-New Haven Medical CenterResidency, Internal Medicine, 2012 - 2015
Tulane University School of MedicineClass of 2012
Certifications & Licensure
NJ State Medical License 2018 - 2025
TX State Medical License 2015 - 2019- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 20 citationsTucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, Jean-Luc Canon, Matthew D Galsky
Journal of Clinical Oncology. 2023-12-20 - 8 citationsEZH2 inhibition for epithelioid sarcoma and follicular lymphoma.Roman Groisberg, Vivek Subbiah
The Lancet. Oncology. 2020-10-06 - 28 citationsBAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma.Janice M Mehnert, Tara C Mitchell, Alexander C Huang, Tomas S Aleman, Benjamin J Kim
Clinical Cancer Research. 2022-03-15
Press Mentions
New Brunswick Cancer Survivor Excited for Construction of New HospitalJune 25th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
